Roche and Blueprint signed an agreement worth 1.7 billion dollars on the joint development of genetic methods of treatment of malignant tumors. Experimental therapy is designed for patients with rare tumors, writes Reuters.
Under the agreement, Roche will pay 675 million dollars and will hold an equity investment in the capital of the Blueprint for rights to palsetine (pralsetinib). It is expected that this drug, used for treatment of non-small cell lung cancer with RET rearrangement may be approved by the FDA this fall.
The company also Blueprint can get from Roche another 927 million USD in case of registration of the drug and its success in the market.